Published in Biochem Soc Trans on October 01, 2015
AKT/PKB Signaling: Navigating the Network. Cell (2017) 0.87
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget (2016) 0.85
The ribosome in action: Tuning of translational efficiency and protein folding. Protein Sci (2016) 0.83
mTOR inhibitors in cancer therapy. F1000Res (2016) 0.79
Human eIF3: from 'blobology' to biological insight. Philos Trans R Soc Lond B Biol Sci (2017) 0.78
FXR1a-associated microRNP: a driver of specialized non-canonical translation in quiescent conditions. RNA Biol (2016) 0.75
AMP-activated Protein Kinase Up-regulates Mitogen-activated Protein (MAP) Kinase-interacting Serine/Threonine Kinase 1a-dependent Phosphorylation of Eukaryotic Translation Initiation Factor 4E. J Biol Chem (2016) 0.75
Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation. PLoS One (2016) 0.75
Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo. Oncotarget (2017) 0.75
Auxin Signaling in Regulation of Plant Translation Reinitiation. Front Plant Sci (2017) 0.75
How Ribosomes Translate Cancer. Cancer Discov (2017) 0.75
Ribosomopathy-like properties of murine and human cancers. PLoS One (2017) 0.75
Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib. Mol Oncol (2017) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
mTOR signaling in growth control and disease. Cell (2012) 29.21
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem (1999) 14.59
Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 14.51
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol (2010) 11.19
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature (1994) 9.30
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev (1999) 8.14
Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci U S A (1986) 8.00
Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell (1985) 7.95
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (1990) 7.74
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. EMBO J (1996) 7.28
The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol (1995) 6.99
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev (1998) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci (2001) 6.66
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Cancer invasion and the microenvironment: plasticity and reciprocity. Cell (2011) 6.36
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res (1999) 4.66
MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J (1997) 4.39
Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev (2005) 3.92
mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J (1992) 3.66
The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. RNA (2001) 3.65
Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A (1996) 3.55
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol (1999) 3.46
Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature (2012) 3.13
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Methylmercury hydroxide enhancement of translation and transcription of ovalbumin and conalbumin mRNA's. J Biol Chem (1979) 3.08
Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08
Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 3.02
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature (2014) 2.84
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
Regulation of mTORC1 by amino acids. Trends Cell Biol (2014) 2.64
mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol (2011) 2.41
The scanning mechanism of eukaryotic translation initiation. Annu Rev Biochem (2014) 2.41
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature (2014) 2.20
Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol (2001) 2.19
Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell (2012) 2.19
4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem (1998) 2.17
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA (2010) 2.11
The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol Cell Biol (1992) 2.10
Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res (2004) 2.06
Targeting the translation machinery in cancer. Nat Rev Drug Discov (2015) 1.98
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb Perspect Biol (2012) 1.73
Translational repression by a complex between the iron-responsive element of ferritin mRNA and its specific cytoplasmic binding protein is position-dependent in vivo. EMBO J (1990) 1.70
Control of mammalian translation by mRNA structure near caps. RNA (2006) 1.66
Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist (2007) 1.61
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
5'-Conformation of capped alfalfa mosaic virus ribonucleic acid 4 may reflect its independence of the cap structure or of cap-binding protein for efficient translation. Biochemistry (1983) 1.56
Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A (2010) 1.55
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep (2014) 1.55
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res (2011) 1.35
Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer (1993) 1.35
Upregulation of renal BSC1 and TSC in prenatally programmed hypertension. Am J Physiol Renal Physiol (2002) 1.26
Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci U S A (2013) 1.23
Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res (2015) 1.23
Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012) 1.17
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (2010) 1.16
The influence of 5'-secondary structures upon ribosome binding to mRNA during translation in yeast. J Biol Chem (1993) 1.16
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci (2013) 1.06
Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med (2014) 1.05
Identification of differential translation in genome wide studies. Proc Natl Acad Sci U S A (2010) 1.05
Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene (2014) 1.04
Interaction of the eukaryotic initiation factor 4E with 4E-BP2 at a dynamic bipartite interface. Structure (2013) 1.02
The race to decipher the top secrets of TOP mRNAs. Biochim Biophys Acta (2014) 1.02
Immunohistochemical profile and morphology in triple - negative breast cancers. J Clin Diagn Res (2013) 1.00
Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol (2009) 0.99
eIF4F suppression in breast cancer affects maintenance and progression. Oncogene (2012) 0.99
Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. Med Res Rev (2012) 0.98
Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle (2008) 0.97
Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2001) 0.97
Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. J Mol Cell Biol (2014) 0.95
mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget (2012) 0.93
Mnks, eIF4E phosphorylation and cancer. Biochim Biophys Acta (2014) 0.92
Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol Cell (2015) 0.91
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer (2012) 0.89
4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation. Nat Commun (2014) 0.88